Jacquet, E <br/><br/>
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  05 2018 
 - 93-101 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2018.03.013  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Aromatase Inhibitors--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Breast Neoplasms, Male--drug therapy<br/>Databases, Factual<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neoplasm Metastasis<br/>Receptor, ErbB-2--genetics<br/>Retrospective Studies<br/>Survival Analysis<br/>Young Adult